# GMP Manual

## Contents

1. **Pharmaceutical Quality System (PQS)**

   1.A Preface

   1.B The road to a Pharmaceutical Quality System

   1.C Introduction to the PQS

      1.C.1 General requirements
      1.C.2 Documentation

   1.D Main elements of a PQS

      1.D.1 Management responsibility
      1.D.2 Resource management
      1.D.3 Manufacturing operations
      1.D.4 Evaluation activities

   1.E Essentials of a PQS

      1.E.1 Principles of a process
      1.E.2 Process mapping
      1.E.3 Responsibilities
      1.E.4 Key Performance Indicators (KPIs)

   1.F Practical implementation of a PQS

      1.F.1 Assistance for implementation
      1.F.2 Organizational aspects
      1.F.3 Process of developing documents
      1.F.4 Document hierarchy

   1.G Structure of a PQS quality manual – example

   1.H Correlation between GMP requirements (WHO) and ISO 9001:2000

   1.I References

2. **Personnel**

   2.A Place of work and job descriptions

   2.B Requirements of the personnel

      2.B.1 Qualification requirements
      2.B.2 Health requirements

---

GMP Manual (Up11) © Maas & Peither AG – GMP Publishing
GMP Manual Contents

2.C Training
2.C.1 Purpose of training 2.C (1)
2.C.2 Responsibility for training 2.C (1)
2.C.3 Requirements profiles/learning objectives 2.C (2)
2.C.4 Training contents and target groups 2.C (3)
2.C.5 Training planning 2.C (4)
2.C.6 Carrying out 2.C (4)
2.C.7 Reviewing the training and the training system 2.C (8)
2.C.8 Documentation 2.C (11)

2.D Function owners subject to public law
2.D.1 Qualified Person (QP) 2.D (1)
2.D.2 Head of Production 2.D (12)
2.D.3 Head of Quality Control 2.D (17)
2.D.4 Qualified Person in Accordance with Article 103 of Guideline 2001/83/EC 2.D (21)
2.D.6 Medical sales representatives 2.D (26)

3 Premises

3.A Official Requirements
3.A.1 Location, connection to other rooms 3.A (4)
3.A.2 Size, area, height 3.A (5)
3.A.3 Installation and supply of utilities 3.A (7)
3.A.4 Lighting, ventilation, air-conditioning 3.A (7)
3.A.5 Hygienic construction 3.A (8)

3.B Material flow, personnel flow and layout
3.B.1 Material flow 3.B (1)
3.B.3 Layout 3.B (4)
3.B.4 Design concepts in FDA’s Sterile Drug Products Produced by Aseptic Processing guideline 3.B (5)

3.C Room classes
3.C.1 General GMP Requirements for Premises 3.C (1)
3.C.2 GMP Requirements for Cleanrooms: Air Cleanliness Grades 3.C (1)
3.C.3 Corresponding FDA Determinations 3.C (4)
3.C.4 GMP Requirements for Premises 3.C (6)
3.C.5 Room-specific Allocation of Air Cleanliness Stipulations 3.C (7)
3.C.6 Cleanliness Zoning Concepts 3.C (9)
3.C.7 Converting GMP Stipulations into Reality 3.C (12)
### 3.D Construction elements
- 3.D.1 Walls
- 3.D.2 Doors and windows
- 3.D.3 Floors
- 3.D.4 Ceilings

### 3.E Barrier systems and isolators
- 3.E.1 Protection concepts for maximized sterility assurance
- 3.E.2 Pharmaceutical isolator technology
- 3.E.3 Restricted access barrier systems (RABS technology)
- 3.E.4 Application options for RABS and isolators

### 3.F Building services
- 3.F.1 Basic requirements for installation
- 3.F.2 Heating
- 3.F.3 Sanitary plumbing and sewage
- 3.F.4 Electrical installations incl. IT-management and control systems
- 3.F.5 Qualification

### 3.G Heating Ventilation Air Conditioning (HVAC)
- 3.G.1 Introduction
- 3.G.2 Room ventilation systems
- 3.G.3 Filters
- 3.G.4 Principles for the design and planning of air conditioning ventilation systems
- 3.G.5 Design criteria for the ventilation of premises
- 3.G.6 Maintenance of air ventilation systems

### 3.H Process Gases
- 3.H.1 Quality Requirements
- 3.H.2 Generation, Storage and Distribution
- 3.H.3 System design
- 3.H.4 Qualification and monitoring

### 3.I Qualification of premises and air-conditioning systems
- 3.I.1 Objectives of qualification
- 3.I.2 Regulatory and normative fundamentals of qualification
- 3.I.3 Project development and qualification
- 3.I.4 Qualification Master Plan
- 3.I.5 Qualification Plans and Qualification Reports
- 3.I.6 Qualification checklists
- 3.I.7 Requirements for measurement and test reports
- 3.I.8 Requalification

### 3.J Monitoring of HVAC systems
- 3.J.1 Objectives of process monitoring
- 3.J.2 Data management stipulations
- 3.J.3 Air cleanliness and other room air data
# Facilities and Equipment

4.A **Introduction**

4.B **Mechanical components**
- 4.B.1 Construction and installation materials
- 4.B.2 GMP-compliant design characteristics
- 4.B.3 Electrical and pneumatic components

4.C **Control**

4.D **Facility concepts**
- 4.D.1 CIP (Cleaning in Place)
- 4.D.2 Isolator technology
- 4.D.3 Connected facilities

4.E **Examples of facility qualification**
- 4.E.1 Design qualification
- 4.E.2 Installation qualification
- 4.E.3 Operational qualification

4.F **Technical documentation**
- 4.F.1 Necessity
- 4.F.2 Scope and content
- 4.F.3 Administration of the technical documentation
- 4.F.4 Log book

4.G **Calibration**
- 4.G.1 Definitions
- 4.G.2 Procedure
- 4.G.3 Documentation
- 4.G.4 Administration of scheduled calibration dates/times

4.H **Maintenance**
- 4.H.1 Types of maintenance
- 4.H.2 GMP-conforming maintenance
- 4.H.3 Systems for maintenance

4.I **CIP (Cleaning in Place)**
- 4.I.1 Introduction
- 4.I.2 CIP systems
- 4.I.3 GMP-conforming design of CIP facilities
- 4.I.4 Nozzle heads for container cleaning
4.I.5 Measuring technology 4.I (13)
4.I.6 Realisation of cleaning systems 4.I (15)

4.J Containment (personnel protection) in solids handling
4.J.1 Significance 4.J (1)
4.J.2 Definition of terms 4.J (3)
4.J.3 Containment grades of products 4.J (3)
4.J.5 Example of containment facility planning 4.J (7)
4.J.6 Containment weak points 4.J (15)
4.J.7 Containment systems for filling and emptying drums 4.J (16)
4.J.8 Container systems 4.J (23)

4.K Process control systems
4.K.1 Definitions 4.K (1)
4.K.2 Features of process control systems 4.K (2)
4.K.3 How to use process control systems 4.K (5)
4.K.4 Carrying out a process control system project 4.K (6)
4.K.5 Qualification of process control systems 4.K (7)

4.L Hygienic (sanitary) design when using solids
4.L.1 Introduction 4.L (1)
4.L.2 Surfaces 4.L (3)
4.L.4 Connections 4.L (11)
4.L.5 Hoists and roller conveyors 4.L (22)
4.L.6 Pneumatic conveyor system 4.L (25)
4.L.7 Dosing systems 4.L (26)
4.L.8 Platforms and stands 4.L (28)
4.L.9 Clean room installations 4.L (31)

5 Pharmaceutical Water

5.A Water types
5.A.1 Potable water 5.A (2)
5.A.2 Purified water 5.A (3)
5.A.3 Highly purified water 5.A (5)
5.A.4 Water for injection 5.A (7)

5.B Generation of pharmaceutical water
5.B.1 Purified water (PW) 5.B (2)
5.B.2 Water for injection (WFI) 5.B (11)
5.B.3 Purification of pharmaceutical water treatment systems 5.B (14)
5.C Distribution and storage of pharmaceutical water
5.C.1 Loop 5.C (1)
5.C.2 Fixtures 5.C (6)
5.C.3 Measuring technique 5.C (7)
5.C.4 Formation of biofilms 5.C (21)
5.C.5 Rouging 5.C (23)
5.C.6 Buffering of ultra pure water 5.C (27)
5.C.7 Loop with subloops 5.C (29)

5.D Qualification of water supplies
5.D.1 Introduction 5.D (1)
5.D.2 Risk analysis 5.D (3)
5.D.3 Design qualification 5.D (8)
5.D.5 Operational qualification (OQ) 5.D (28)
5.D.6 Transfer to the user 5.D (36)
5.D.7 Process validation/performance qualification (PQ) 5.D (42)
5.D.8 Qualification report 5.D (47)

5.E Operation of water supplies
5.E.1 Procedures to reduce microbial counts 5.E (1)
5.E.2 Maintenance of a water supply 5.E (4)
5.E.3 Calibration of measuring systems 5.E (10)
5.E.4 Change control 5.E (11)
5.E.5 Requalification 5.E (13)
5.E.6 Decommissioning/uninstalling 5.E (14)

5.F Pure steam systems
5.F.1 Physical principles 5.F (1)
5.F.2 Quality requirements for pure steam 5.F (3)
5.F.3 Pure steam generation 5.F (6)
5.F.4 Pure steam distribution system 5.F (10)

6 Qualification

6.A Official requirements
6.A.1 Legal aspects of qualification 6.A (1)
6.A.2 Documentation of the qualification 6.A (4)
6.A.3 Design Qualification (DQ) 6.A (5)
6.A.4 Installation Qualification (IQ) 6.A (8)
6.A.5 Operational Qualification (OQ) 6.A (9)
6.A.6 Performance Qualification (PQ) 6.A (10)
6.A.7 Qualification of established facilities 6.A (11)
6.A.8 Requalification 6.A (13)
### 6.B Preparation of the qualification
- **6.B.1 Commissioning** 6.B (1)
- **6.B.2 Sequence** 6.B (5)
- **6.B.3 Qualification team** 6.B (6)
- **6.B.4 Responsibilities** 6.B (6)
- **6.B.5 Qualification by external service providers** 6.B (6)
- **6.B.6 Risk analysis** 6.B (10)

### 6.C Qualification documentation
- **6.C.1 Qualification master plan** 6.C (2)
- **6.C.2 Qualification plan** 6.C (3)
- **6.C.3 Qualification report** 6.C (9)
- **6.C.4 Labeling of the qualification status** 6.C (10)

### 6.D Design qualification (DQ)
- **6.D.1 User requirements (user specifications)** 6.D (3)

### 6.E Installation qualification (IQ)
- **6.E.1 Examples of IQ plans** 6.E (3)
- **6.E.2 Example: Fluid bed equipment** 6.E (22)

### 6.F Operational qualification (OQ)
- **6.F.1 Examples of OQ plans** 6.F (3)
- **6.F.2 Example: Fluid bed dryer** 6.F (13)

### 6.G Performance qualification (PQ)
- **6.H.1 Retrospective qualification** 6.H (1)
- **6.H.2 Requalification** 6.H (2)
- **6.H.3 Content of a review** 6.H (3)
- **6.H.5 Qualification of simple equipment** 6.H (7)

### 7 Process Validation

#### 7.A Official requirements
- **7.A.1 Regulative aspects** 7.A (1)
- **7.A.3 Types of process validation** 7.A (18)
- **7.A.4 Maintaining the validated status** 7.A (19)
- **7.A.5 Documentation of process validation** 7.A (23)

#### 7.B Validation – a key element of quality assurance
8 Cleaning Validation

8.A Official requirements

8.B How to validate cleaning procedures
8.B.1 Optimization of cleaning procedures
8.B.2 Compilation of cleaning instructions
8.B.3 Validating manual and automated cleaning procedures

8.C Cleaning validation master plan

8.D Establishing the scope of validation
8.D.1 Bracketing: determination of critical substances
8.D.2 Matrixing: determination of equipment-specific validation protocols

8.E Acceptance criteria and limit calculation
8.E.1 Calculation of active pharmaceutical ingredient residues
8.E.2 Calculation of cleansing agent residues
8.E.3 Determination of the microbial status

8.F Sampling procedures
8.F.1 Swab test
8.F.2 Rinse test
8.F.3 Other procedures
8.F.4 Selection of the appropriate sampling procedure
8.F.5 Microbiological testing of surfaces

8.G Analytical procedures
8.G.1 Requirements for method validation
8.G.2 Selection of the appropriate analytical procedure

8.H Documentation
8.H.1 Validation protocol
8.H.2 Validation report
8.H.3 Other documents

8.I Maintenance of the validated status
8.I.1 Changes and deviations
8.I.2 Change control
8.I.3 Revalidation
8.I.4 New products and equipment
8.I.5 Deviations

8.J Cleaning validation documentation (example)

8.K References
9 Computer Validation

9.A Introduction and basic terminology

9.B Regulatory aspects
  9.B.1 Europe 9.B (1)
  9.B.3 USA 9.B (4)

9.C Life cycle of software and systems
  9.C.1 “V-Model” 9.C (2)
  9.C.3 Purchasing commercial of the shelf systems 9.C (6)
  9.C.4 Configuration and customisation 9.C (7)

9.D Risk analysis and system classification
  9.D.3 Risk management at the level of user requirements 9.D (14)

9.E Validation of computerised systems
  9.E.3 Specifications (user requirements/technical specification) for hardware and software 9.E (8)
  9.E.4 Unit, integration and acceptance tests 9.E (11)
  9.E.6 Data migration and start-up 9.E (18)
  9.E.8 Dealing with existing systems (legacy systems) 9.E (34)

9.F Operation of computerised systems
  9.F.1 System description 9.F (1)
  9.F.2 User training 9.F (1)
  9.F.3 Standard operating procedures (SOPs) 9.F (1)
  9.F.4 Authorised access and security (virus protection) 9.F (2)
  9.F.5 Data backup and archiving 9.F (5)
  9.F.7 Change management and error reporting 9.F (8)
  9.F.8 Periodic review 9.F (10)
9.G External service providers
9.G.1 Relocation of activities (outsourcing, offshoring, nearshoring, backshoring) 9.G (1)
9.G.2 Service level agreement 9.G (2)
9.G.3 Auditing of suppliers and service providers 9.G (8)

9.H References

10 Considerations on Risk Management

10.A Introduction and Principles
10.A.1 Advantages of Risk Management 10.A (2)
10.A.2 Considerations on the Risk-Based Approach 10.A (4)
10.A.3 Regulatory Environment 10.A (7)
10.A.4 Objectives 10.A (12)
10.A.5 Science-Based Approach 10.A (13)
10.A.6 Summary 10.A (14)

10.B Basic Consideration on Implementing Risk Management Into a Process
10.B.1 Areas of Hazards 10.B (1)
10.B.2 Prerequisites 10.B (3)
10.B.3 Use of Knowledge and Experience 10.B (5)
10.B.7 Commitment of Management 10.B (7)
10.B.8 Project Team 10.B (8)
10.B.9 Analysis of Existing Risk Management Approaches 10.B (8)
10.B.10 Standardization of Methods and Tools 10.B (9)
10.B.11 Considerations on Risk Based Behavior 10.B (9)

10.C Details on Using Risk Management Principles as Behavior
10.C.1 Application to the QM System 10.C (1)
10.C.2 The Team 10.C (2)
10.C.3 Assessment Criteria 10.C (3)
10.C.4 Procedure to Determine Conclusions 10.C (4)

10.D Methodologies to be Used to Facilitate Risk Management

10.E Using Process Mapping

10.F Using a Fishbone Diagram
10.F.1 Create a Fish Bone Diagram 10.F (2)
10.F.2 Advantages and Disadvantages 10.F (4)
10.G Informal Use of Risk Management

10.H Fault Tree Analysis (FTA)
10.H.1 Basic Principles
10.H.2 Objective: What a FTA Can Do and Where to Use It
10.H.3 How to Run the Process of a FTA
10.H.4 Prerequisites for an FTA
10.H.5 Execution of an FTA
10.H.6 Advantages and Disadvantages of an FTA

10.I Failure Mode Effects Analysis (FMEA)
10.I.1 Objectives and Areas of Application
10.I.2 General Items on the FMEA Process
10.I.3 Implementation of FMEA in a Project
10.I.4 Advantages and Disadvantages of an FMEA
10.I.5 Application Example of a Modified FMEA

10.J Hazard Analysis of Critical Control Points (HACCP)
10.J.1 Prerequisite and Result to be Expected
10.J.2 Advantages and Disadvantages
10.J.3 Application Example

10.K Conclusion

11 Production

11.A Sanitation
11.A.1 Organisational prerequisites
11.A.2 Sources of contamination
11.A.3 Responsibilities and implementation

11.B Personnel hygiene
11.B.1 Clothing
11.B.2 Code of Conduct
11.B.3 Hand disinfection
11.B.4 Health requirements
11.B.5 Training

11.C Production hygiene
11.C.1 Sources of contamination
11.C.2 Cleaning
11.C.3 Disinfection

11.D Sanitation programme
11.D.1 Organisation of room cleaning
11.D.2 Documentation

11.E Environmental monitoring
11.E.1 General
11.E.2 Sampling plan 11.E (3)
11.E.3 Establishment of limits and frequencies 11.E (4)
11.E.4 Methods 11.E (9)
11.E.5 Investigation areas 11.E (11)

11.F GMP in the production process

11.G Weigh-in
11.G.1 Legal requirements 11.G (1)

11.H Identification
11.H.1 Handling of labels 11.H (1)
11.H.2 Labelling of starting materials 11.H (2)
11.H.3 Labelling of equipment and containers 11.H (3)
11.H.4 Labelling of rooms 11.H (7)

11.I In-process control
11.I.1 Objectives 11.I (2)
11.I.2 Organisation and responsibilities 11.I (3)
11.I.3 Carrying out 11.I (4)
11.I.4 Documentation and evaluation of data 11.I (8)

11.J Prevention of cross-contamination
11.J.1 Causes of cross-contamination 11.J (1)
11.J.2 Measures to prevent cross-contamination 11.J (5)

11.K Deviations
11.K.1 Definition 11.K (1)
11.K.2 Procedure 11.K (2)
11.K.7 SOP “deviations” – (example) 11.K (9)
11.K.8 Check-list for deviation handling 11.K (14)

11.L Reworking
11.L.1 Definitions 11.L (1)
11.L.2 Procedure 11.L (2)
11.L.3 Rework / Reprocessing of rejected products 11.L (4)
11.L.4 Rework of returned products 11.L (8)
11.L.5 Rework of products that have not been rejected 11.L (8)
11.M  Warehouse and logistics
   11.M.1  Regulatory requirements  11.M (1)
   11.M.2  Stock management system  11.M (2)
   11.M.3  Responsibilities  11.M (6)
   11.M.5  Storage areas  11.M (7)
   11.M.6  Storage conditions  11.M (13)
   11.M.7  Sanitation and pest control  11.M (16)
   11.M.9  Process Flow  11.M (22)

11.N  Transportation
   11.N.1  Requirements for logistic service providers  11.N (2)
   11.N.2  Transportation challenges and monitoring devices  11.N (5)
   11.N.3  Cool/Cold Chain Distribution  11.N (9)
   11.N.4  Temperature Profiles  11.N (13)
   11.N.5  Transportation Risks  11.N (18)

11.O  References

12  Sterile Production

12.A  Introduction
   12.A.1  Manufacturing products that can be sterilised in the final container  12.A (2)
   12.A.2  Aseptic processing  12.A (3)
   12.A.3  Production areas/premises  12.A (4)
   12.A.4  Production equipment  12.A (7)

12.B  Air Lock Concepts
   12.B.1  Personnel locks in the clean area  12.B (1)

12.C  Manufacturing the solution
   12.C.1  Starting materials  12.C (1)
   12.C.2  Solution batch  12.C (4)
   12.C.3  Testing the bioburden  12.C (8)
   12.C.4  Sterile filtration  12.C (9)

12.D  Washing processes
   12.D.1  Stoppers  12.D (1)

12.E  Filling
   12.E.1  Filling equipment for solutions  12.E (1)
12.E.5 Culture medium filling (Media Fill) 12.E (8)

12.F Steam sterilisation
12.F.1 Sterilisers 12.F (1)
12.F.2 Description of the procedure 12.F (2)
12.F.3 Qualification of a steam steriliser 12.F (6)
12.F.4 Validation of the steam sterilisation process 12.F (11)

12.G Microbiological monitoring
12.G.1 Sources of contamination 12.G (1)
12.G.2 Room classification 12.G (2)
12.G.6 Measure if levels are exceeded 12.G (22)

12.H Test for sterility
12.H.1 Parametric release 12.H (1)
12.H.2 Sterility test 12.H (3)
12.H.4 Number of samples 12.H (11)
12.H.6 Reading and evaluating 12.H (12)
12.H.7 Procedure in the event of culture medium turbidity 12.H (15)
12.H.8 Culture media 12.H (16)
12.H.9 Culture media controls 12.H (17)

12.I Testing for tightness and particles
12.I.1 Testing for tightness 12.I (1)
12.I.2 Particle test 12.I (5)
12.I.3 Sequence of operation 12.I (12)

12.J Freeze drying
12.J.1 Description of the procedure 12.J (1)
12.J.3 Validation of the freeze drying process 12.J (9)

12.K Dry Heat Sterilisation
12.K.1 Description of the procedure 12.K (2)
12.K.3 Qualification of a sterilisation tunnel 12.K (5)
12.K.4 Validation of the sterilisation process 12.K (8)
## 13 Packaging

### 13.A Packaging material
- 13.A.1 Responsibilities
- 13.A.2 Contents
- 13.A.3 Materials
- 13.A.4 Protection against counterfeit medicinal products
- 13.A.5 Packaging material testing

### 13.B Packaging process
- 13.B.1 Allocation of packaging material
- 13.B.2 Line clearance
- 13.B.3 Labelling
- 13.B.4 Control functions
- 13.B.5 Release for production
- 13.B.6 In-process controls
- 13.B.7 Cleaning primary containers
- 13.B.8 Labelling
- 13.B.9 Variable data
- 13.B.10 Imprints
- 13.B.11 Reconciliation
- 13.B.12 Safety features
- 13.B.13 Completion of a packaging process

### 13.C Qualification of a packaging line
- 13.C.1 Master qualification plan
- 13.C.2 Design qualification (DQ)
- 13.C.3 Installation qualification (IQ)
- 13.C.4 Operational qualification (OQ)
- 13.C.5 Performance qualification (PQ)

## 14 Laboratory Controls

### 14.A Sampling
- 14.A.1 Requirements
- 14.A.2 Sampling plan (instructions)
- 14.A.3 Notes for the sampling process

### 14.B Reagents
- 14.B.1 Labeling
- 14.B.2 Usage and stability
- 14.B.3 Documentation

### 14.C Standards and reference substances
- 14.C.1 Definition of different standards and their areas of use
- 14.C.2 Handling, storage and stability
<table>
<thead>
<tr>
<th>14.D</th>
<th>Qualifying laboratory instruments</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.D.1</td>
<td>Qualification protocols and reports</td>
</tr>
<tr>
<td>14.D.2</td>
<td>System suitability test (SST)</td>
</tr>
<tr>
<td>14.E</td>
<td>Calibration in the lab</td>
</tr>
<tr>
<td>14.E.1</td>
<td>Definitions</td>
</tr>
<tr>
<td>14.E.2</td>
<td>Calibration instructions and record</td>
</tr>
<tr>
<td>14.E.3</td>
<td>Examples</td>
</tr>
<tr>
<td>14.E.4</td>
<td>Decision</td>
</tr>
<tr>
<td>14.F</td>
<td>Validation of analytical methods</td>
</tr>
<tr>
<td>14.F.1</td>
<td>Principles</td>
</tr>
<tr>
<td>14.F.2</td>
<td>Definitions of the parameters</td>
</tr>
<tr>
<td>14.F.3</td>
<td>Documentation</td>
</tr>
<tr>
<td>14.F.4</td>
<td>Revalidation</td>
</tr>
<tr>
<td>14.G</td>
<td>Stability testing</td>
</tr>
<tr>
<td>14.G.1</td>
<td>ICH guidelines for stability tests</td>
</tr>
<tr>
<td>14.G.2</td>
<td>Storage and storage conditions</td>
</tr>
<tr>
<td>14.G.3</td>
<td>Analyses</td>
</tr>
<tr>
<td>14.G.4</td>
<td>Reduction of the study design</td>
</tr>
<tr>
<td>14.G.5</td>
<td>Stability testing in the marketing phase</td>
</tr>
<tr>
<td>14.G.6</td>
<td>Defining the retest period for an active pharmaceutical ingredient and the shelf life for a drug product through evaluation of stability data (ICH Q1E)</td>
</tr>
<tr>
<td>14.G.7</td>
<td>Decision tree for data evaluation for retest period or for APIs or drug products (excluding frozen products)</td>
</tr>
<tr>
<td>14.G.8</td>
<td>Procedure for statistical analysis</td>
</tr>
<tr>
<td>14.G.9</td>
<td>Examples of the statistical evaluation of stability data</td>
</tr>
<tr>
<td>14.H</td>
<td>Out-of-specification results</td>
</tr>
<tr>
<td>14.H.1</td>
<td>Significance</td>
</tr>
<tr>
<td>14.H.2</td>
<td>Definitions</td>
</tr>
<tr>
<td>14.H.3</td>
<td>FDA OOS Guidance</td>
</tr>
<tr>
<td>14.H.4</td>
<td>Example for handling of an OOS result</td>
</tr>
<tr>
<td>14.H.5</td>
<td>Trend tracking</td>
</tr>
<tr>
<td>14.I</td>
<td>Raw data documentation</td>
</tr>
<tr>
<td>14.I.1</td>
<td>Principles</td>
</tr>
<tr>
<td>14.I.2</td>
<td>Single sheet documentation system</td>
</tr>
<tr>
<td>14.J</td>
<td>Batch release</td>
</tr>
<tr>
<td>14.J.1</td>
<td>Certification by a Qualified Person and release in accordance with EC GMP Guidelines</td>
</tr>
<tr>
<td>14.J.2</td>
<td>Responsibility for issuing the release</td>
</tr>
<tr>
<td>14.J.3</td>
<td>Publication of release</td>
</tr>
<tr>
<td>14.J.4</td>
<td>Release procedures in practice</td>
</tr>
</tbody>
</table>
14.K Microbiological testing
14.K.1 Total microbial count 14.K (2)

14.L Pharmacopoeias
14.L.1 Structure of Pharmacopoeias 14.L (1)
14.L.2 General considerations 14.L (2)
14.L.3 Development of Monographs 14.L (3)
14.L.4 European Pharmacopoeia (Ph Eur) 14.L (4)
14.L.5 British Pharmacopoeia (BP) 14.L (7)
14.L.8 International Pharmacopoeia (Ph Int) 14.L (13)
14.L.9 Harmonization 14.L (14)

14.M References

15 Documentation

15.A Official requirements
15.A.1 GMP-requirements managed and reviewed according to German pharma business regulations 15.A (1)
15.A.2 Requirements of the EU GMP Guideline 15.A (4)
15.A.3 Requirements of the US GMP Regulations 15.A (8)
15.A.4 Formal requirements 15.A (13)
15.A.5 Management and revision documentation 15.A (17)

15.B GMP-conforming documentation
15.B.1 Handwritten entries 15.B (1)
15.B.2 Archiving 15.B (2)
15.B.3 Master-SOP – “GMP-conforming documentation” 15.B (3)

15.C Batch documentation
15.C.1 Manufacturing instructions/record 15.C (3)
15.C.2 Packaging instruction and batch packaging record 15.C (26)
15.C.3 Electronic batch recording 15.C (28)
15.C.4 Testing procedures and test protocol 15.C (31)
15.C.5 Batch record review 15.C (36)

15.D Standard operating procedures (SOPs)
15.D.1 Compilation 15.D (2)
15.D.2 Approval and implementation 15.D (7)
15.D.3 Training 15.D (7)
15.D.4 Usage 15.D (8)
15.D.5 Review 15.D (9)
15.D.6 Changes 15.D (9)
15.D.7 Withdrawing an operating procedure 15.D (10)
15.D.8 Administration 15.D (10)
15.D.9 Archiving 15.D (12)
15.D.10 Example of an SOP “Compilation and
administration of operating procedures” 15.D (13)

15.E Site master file
15.E.1 Introduction 15.E (1)
15.E.2 Design 15.E (1)

15.F Annual product review / Product quality review
15.F.1 Documents required for an annual product review 15.F (4)
15.F.2 Annual product review report 15.F (6)
15.F.3 Collaboration with a contract manufacturer 15.F (8)
15.F.4 Example: annual product review 15.F (9)
15.F.5 Master-SOP for the annual product review 15.F (14)

16 Research and Development

16.A General conditions and legal requirements

16.B Development phases and GMP requirements
16.B.1 Formulation development 16.B (4)
16.B.2 Analytical development 16.B (7)
16.B.3 Manufacturing and testing of stability samples 16.B (11)
16.B.4 Packaging development 16.B (14)
16.B.6 Cleaning verification and validation 16.B (19)
16.B.7 Process optimization:
Basic principles for process validation 16.B (22)
16.B.9 Handover to other manufacturing sites 16.B (27)

16.C Interfaces to GLP and GCP
16.C.1 GLP –Good Laboratory Practice 16.C (1)
16.C.3 Interfaces between the areas regulated by GMP
and those regulated by GCP 16.C (10)

16.D Manufacture and control of clinical samples
16.D.1 Prerequisites for the approval of clinical investigations 16.D (1)
16.D.2 Manufacturing of clinical samples and comparator drugs 16.D (2)
16.E Documentation and recording of changes during development
16.F Development report

17 Contractors and Suppliers

17.A Contract manufacture
17.A.1 Reasons for contract manufacture 17.A (1)
17.A.2 Procedure for assigning manufacturing contracts 17.A (3)
17.A.3 Duties of the contract giver 17.A (9)
17.A.4 Duties of the contract acceptor 17.A (12)
17.A.5 Contract manufacturer agreement 17.A (17)
17.A.6 Audits of contract manufacturers 17.A (21)
17.A.7 SOP for assigning manufacturing contracts 17.A (30)
17.A.8 Framework contract for contract manufacture and quality control 17.A (36)

17.B Contract Analysis
17.B.1 Introduction 17.B (1)
17.B.2 Legal background 17.B (2)
17.B.3 Selection of an external testing laboratory 17.B (3)
17.B.4 Liability limitation contract 17.B (5)
17.B.5 Certificate of Analysis 17.B (14)
17.B.6 Transfer of the test to the contract laboratory 17.B (15)

17.C Suppliers
17.C.1 Introduction 17.C (1)
17.C.2 Definitions 17.C (4)
17.C.3 Quality systems 17.C (5)
17.C.4 Records 17.C (14)
17.C.5 Contracts and quality agreements 17.C (17)
17.C.6 Supplier review and controls 17.C (19)
17.C.7 Supplier audits 17.C (21)
17.C.8 Re-evaluation of Suppliers 17.C (26)

17.D References

18 Inspections

18.A Principles

18.B Inspection procedures
18.B.1 System-based 18.B (1)
18.B.2 Product-based 18.B (2)
18.B.3 Procedure-based 18.B (2)
18.B.4 Area-based 18.B (3)
18.C  Inspectors
18.C.1  Technical qualification requirements 18.C (1)
18.C.2  Personal requirements 18.C (3)

18.D  Organization of inspections
18.D.1  Inspection planning 18.D (1)
18.D.2  Inspection preparation 18.D (3)
18.D.3  Carrying out the inspections 18.D (4)

18.E  Self-inspection
18.E.1  Purpose of self-inspection 18.E (1)
18.E.2  Carrying out the self-inspection 18.E (1)
18.E.3  Self-inspection documentation 18.E (3)
18.E.4  Errors and remedial action 18.E (9)
18.E.5  Follow-up activities 18.E (11)

18.F  Inspection of contract manufacturers
18.F.1  Purpose of the inspection of contract manufacturer 18.F (1)
18.F.2  Carrying out inspections of contract manufacturer 18.F (1)
18.F.3  Handling of changes and deviations 18.F (3)

18.G  Inspection of suppliers
18.G.1  Purpose of the supplier inspection 18.G (1)
18.G.2  Carrying out the supplier inspection 18.G (2)

18.H  Questionnaire for preparing GMP-inspections

18.I  References

19  Quality Unit

19.A  General
This chapter will be part of a later update.

19.B.2  Legal background of the European “Qualified Person” regulations 19.B (2)

19.C  Change control
19.C.1  Principles of change control 19.C (1)
19.C.2  Introduction and operation of change control programs 19.C (4)
19.C.3  Documentation 19.C (9)

19.D  References
20 Continual Improvement

20.A Preface

20.B Six Sigma
20.B.1 Definition 20.B (1)
20.B.2 What it is / what it does / how it works 20.B (1)
20.B.5 Tools 20.B (24)
20.B.7 Examples 20.B (26)

20.C Statistical Process Control (SPC)
20.C.1 Definition 20.C (1)
20.C.2 What it is / what it does / how it works 20.C (1)
20.C.5 Tools 20.C (36)
20.C.6 Variations 20.C (36)
20.C.7 Examples 20.C (36)

20.D Process Analytical Technology (PAT)
20.D.1 Definition 20.D (1)

20.E References

21 Active and Inactive Ingredients

21.A GMP for Active Pharmaceutical Ingredients (APIs)
21.A.11 Laboratory controls 21.A (49)
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21.A.13  Change Control</td>
<td>59</td>
</tr>
<tr>
<td>21.A.14  Rejection and re-use of materials</td>
<td>63</td>
</tr>
<tr>
<td>21.A.15  Complaints and Recalls</td>
<td>70</td>
</tr>
<tr>
<td>21.A.16  Contract manufacturers, including laboratories</td>
<td>70</td>
</tr>
<tr>
<td>21.A.17  Agents, brokers, traders, distributors, repackers, and relabellers</td>
<td>72</td>
</tr>
<tr>
<td>21.A.18  Specific guidance for APIs manufactured by cell culture/fermentation</td>
<td>75</td>
</tr>
<tr>
<td>21.A.19  APIs for use in clinical trials</td>
<td>81</td>
</tr>
<tr>
<td>21.B     GMP for APIs – considerations on special topics</td>
<td>1</td>
</tr>
<tr>
<td>21.B.1   Materials management</td>
<td>9</td>
</tr>
<tr>
<td>21.B.2   Production and maintenance</td>
<td>23</td>
</tr>
<tr>
<td>21.B.3   Re-use and recovery of materials</td>
<td>32</td>
</tr>
<tr>
<td>21.B.4   Interaction with brokers</td>
<td>32</td>
</tr>
<tr>
<td>21.C     Excipients</td>
<td>1</td>
</tr>
<tr>
<td>21.C.1   Introduction</td>
<td>6</td>
</tr>
<tr>
<td>21.C.2   Regulatory aspects and guidance documents</td>
<td>36</td>
</tr>
<tr>
<td>21.C.3   Safety, toxicological, and precedence of use issues</td>
<td>39</td>
</tr>
<tr>
<td>21.C.4   Compendial monographs</td>
<td>45</td>
</tr>
<tr>
<td>21.C.5   Excipient Master Files and other filings</td>
<td>48</td>
</tr>
<tr>
<td>21.C.6   Applicability of ICH guidance to excipients</td>
<td>50</td>
</tr>
<tr>
<td>21.C.7   Other aspects critical to the marketing of excipients</td>
<td>10</td>
</tr>
<tr>
<td>21.D     References</td>
<td></td>
</tr>
<tr>
<td>22       Biologics</td>
<td></td>
</tr>
<tr>
<td>23       Medical Devices</td>
<td></td>
</tr>
<tr>
<td>23.A     Introduction</td>
<td>2</td>
</tr>
<tr>
<td>23.A.1   Definition</td>
<td>3</td>
</tr>
<tr>
<td>23.A.2   Types of medical devices</td>
<td>5</td>
</tr>
<tr>
<td>23.A.3   Regulatory background</td>
<td>10</td>
</tr>
<tr>
<td>23.A.4   Process approach to a Quality Management System</td>
<td>10</td>
</tr>
<tr>
<td>23.B     Quality Management System (QMS)</td>
<td>1</td>
</tr>
<tr>
<td>23.B.1   Management responsibility</td>
<td>4</td>
</tr>
<tr>
<td>23.B.2   Quality manual</td>
<td>5</td>
</tr>
<tr>
<td>23.B.3   Quality policy</td>
<td>6</td>
</tr>
<tr>
<td>23.B.4   Quality planning</td>
<td>7</td>
</tr>
<tr>
<td>23.B.5   Management review</td>
<td>10</td>
</tr>
<tr>
<td>23.B.6   Audits</td>
<td></td>
</tr>
<tr>
<td>23.C     Personnel</td>
<td>1</td>
</tr>
<tr>
<td>23.C.1   General</td>
<td>2</td>
</tr>
<tr>
<td>23.C.2   Training</td>
<td></td>
</tr>
</tbody>
</table>
23.C.3 Health, hygiene, practices, and clothing 23.C (3)
23.C.4 Consultants and contractors 23.C (4)

23.D Design control
23.D.1 General 23.D (1)
23.D.2 Design planning 23.D (4)
23.D.4 Design output 23.D (9)
23.D.5 Design review 23.D (10)
23.D.8 Design transfer 23.D (17)
23.D.9 Design changes 23.D (18)
23.D.10 Design history file 23.D (20)

23.E Human factors

23.F Statistical techniques

23.G Risk management

23.H Document and record control
23.H.1 Control of documents 23.H (1)
23.H.2 Control of records 23.H (4)

23.I Production and process controls
23.I.1 Manufacturing materials 23.I (2)
23.I.2 Automated processes 23.I (2)
23.I.3 Sterile products 23.I (3)
23.I.4 Changes 23.I (4)
23.I.5 Material acceptance procedures 23.I (4)

23.J Identification and traceability
23.J.1 Identification 23.J (1)
23.J.2 Traceability 23.J (1)

23.K Buildings, facilities, and equipment
23.K.1 Buildings and facilities 23.K (1)
23.K.2 Environment 23.K (2)
23.K.3 Equipment 23.K (3)

23.L Validation

23.M Purchasing/supplier control
23.M.1 Purchase orders 23.M (3)
23.M.2 Quality agreements 23.M (3)

23.N Packaging and labeling
23.N.1 Packaging 23.N (1)
23.N.2 Manufacturer’s information 23.N (1)
23.O Handling, storage, distribution, installation and servicing
23.O.1 Handling 23.O (1)
23.O.2 Storage 23.O (2)
23.O.3 Distribution 23.O (2)
23.O.4 Installation 23.O (3)
23.O.5 Servicing 23.O (3)

23.P Nonconformance, Corrective Action and Preventive Action
23.P.1 Definitions 23.P (1)
23.P.2 CAPA System 23.P (1)
23.P.4 Advisory notice, device correction or product recall 23.P (5)

23.Q Customer complaints
23.Q.1 Complaint evaluation 23.Q (2)
23.Q.2 Complaint investigation 23.Q (2)

23.R Combination products

23.S References
A  Information
A.1  Empty Chapter
A.2  Empty Chapter
A.3  List of Abbreviations
A.4  Glossary
A.5  Address-Register
A.6  References

B  Japanese Regulations
B.1  MHW Ministerial Ordinance No. 2, 1961: Regulations for Buildings and Facilities of Pharmacies, etc.
B.2  MHLW Ministerial Ordinance No. 136, 2004: Standards for Quality Assurance for Drugs, Quasi-drugs, Cosmetics and Medical Devices
B.3  MHLW Ministerial Ordinance No. 179, 2004: Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs

C  EU Directives and Guidelines
C.1  EU GMP Guide: Introduction
C.4  Part I Basic Requirements for Medicinal Products
C.4.1  Chapter 1: Quality Management
C.4.2  Chapter 2: Personnel
C.4.3  Chapter 3: Premises and Equipment
C.4.4  Chapter 4: Documentation
C.4.5  Chapter 5: Production
C.4.6 Chapter 6: Quality Control
C.4.7 Chapter 7: Contract Manufacture and Analysis
C.4.8 Chapter 8: Complaints and Product Recall
C.4.9 Chapter 9: Self Inspection
C.5 Part II Basic Requirements for Active Substances used as Starting Materials
C.6.1 Annex 1 Manufacture of Sterile Medicinal Products
C.6.2 Annex 2 Manufacture of Biological Medicinal Products for Human Use
C.6.3 Annex 3 Manufacture of Radiopharmaceuticals
C.6.4 Annex 4 Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products
C.6.5 Annex 5 Manufacture of Immunological Veterinary Medicinal Products
C.6.6 Annex 6 Manufacture of Medicinal Gases
C.6.7 Annex 7 Manufacture of Herbal Medicinal Products
C.6.8 Annex 8 Sampling of Starting and Packaging Materials
C.6.9 Annex 9 Manufacture of Liquids, Creams and Ointments
C.6.10 Annex 10 Manufacture of Pressurised Metered Dose Aerosol Preparations for Inhalation
C.6.11 Annex 11 Computerised Systems
C.6.12 Annex 12 Use of Ionising Radiation in the Manufacture of Medicinal Products
| C.6.13 | Annex 13  
|        | Investigational Medicinal Products |
| C.6.14 | Annex 14  
|        | Manufacture of Medicinal Products Derived from Human Blood or Plasma |
| C.6.15 | Annex 15  
|        | Qualification and Validation |
| C.6.16 | Annex 16  
|        | Certification by a Qualified Person and Batch Release |
| C.6.17 | Annex 17  
|        | Parametric Release |
| C.6.18 | Annex 18  
|        | Good Manufacturing Practice for Active Pharmaceutical Ingredients |
| C.6.19 | Annex 19  
|        | Reference and Retention Samples |
| C.6.20 | Annex 20  
|        | Quality Risk Management |
| C.7    | Glossary |
| C.8    | Part III |
| C.8.1  | Explanatory Notes on the preparation of a Site Master File |
| C.9    | Note For Guidance on Quality of Water for Pharmaceutical Use |
| C.10   | Compilation of Community Procedures on Inspections and Exchange of Information |

**D**  
**USA: CFR and FDA Guidelines**

| D.1    | Code of Federal Regulations |
| D.2    | Guidance for Industry  
|        | Process Validation: General Principles and Practices |
| D.3    | Guide to Inspections of High Purity Water Systems |
| D.4    | Guide to Inspections of Validation of Cleaning Processes |
| D.5    | Guide to inspections of oral solid dosage forms pre/post approval issues for development and validation |
| D.6    | Guide to Inspections of Validation Documentation |
| D.7    | Guide to Inspections:  
<p>|        | Computerized Systems in Drug Establishments (2/83) |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>D.8</td>
<td>Guide to Inspections of Pharmaceutical Quality Control Laboratories</td>
</tr>
<tr>
<td>D.9</td>
<td>Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production</td>
</tr>
<tr>
<td>D.10</td>
<td>Guidance for Industry Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice</td>
</tr>
<tr>
<td>D.12</td>
<td>Guidance for Industry Part 11, Electronic Records; Electronic Signatures – Scope and Application</td>
</tr>
<tr>
<td>D.13</td>
<td>21 CFR Part 820 – Quality System Regulation</td>
</tr>
<tr>
<td>D.14</td>
<td>Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations</td>
</tr>
<tr>
<td>D.15</td>
<td>Guidance for Industry cGMP for Phase 1 Investigational Drugs</td>
</tr>
<tr>
<td>D.16</td>
<td>Federal Food, Drug, and Cosmetic Act (FD&amp;C Act)</td>
</tr>
<tr>
<td>D.17</td>
<td>Pre-Approval Inspections</td>
</tr>
</tbody>
</table>

**E**

**ICH-Guidelines**

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>E.1.A</td>
<td>ICH Q1A(R2): Stability Testing of New Drug Substances and Products</td>
</tr>
<tr>
<td>E.1.C</td>
<td>ICH Q1C: Stability Testing for New Dosage Forms</td>
</tr>
<tr>
<td>E.1.D</td>
<td>ICH Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products</td>
</tr>
<tr>
<td>E.1.E</td>
<td>ICH Q1E: Evaluation of Stability Data</td>
</tr>
<tr>
<td>E.2</td>
<td>ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology</td>
</tr>
</tbody>
</table>
E.3.A  ICH Q3A(R2): Impurities in New Drug Substances
E.3.B  ICH Q3B(R2): Impurities in New Drug Products
E.3.C  ICH Q3C(R5): Impurities: Guideline for Residual Solvents
E.4   ICH Q4: Pharmacopoeias
E.4.A  ICH Q4A: Pharmacopoeial Harmonisation
E.4.B  ICH Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions
E.4.B.3 ICH Q4B Annex 4C:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Microbiological Examination
of Non-Sterile Products: Acceptance Criteria For Pharmaceutical
Preparations and Substances for Pharmaceutical Use –
General Chapter

E.4.B.5 ICH Q4B Annex 5:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Disintegration Test –
General Chapter

E.4.B.6 ICH Q4B Annex 6:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Uniformity of Dosage Units –
General Chapter

E.4.B.7 ICH Q4B Annex 7:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Dissolution Test –
General Chapter

E.4.B.8 ICH Q4B Annex 8:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Sterility Test –
General Chapter

E.4.B.9 ICH Q4B Annex 9:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Tablet Friability –
General Chapter

E.4.B.10 ICH Q4B Annex 10:
Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Polyacrylamide Gel Electrophoresis
– General Chapter

E.5.A ICH Q5A(R1):
Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of
Human or Animal Origin

E.5.B ICH Q5B:
Quality of Biotechnological Products: Analysis of the Expression Construct
in Cells Used for Production of R-DNA Derived Protein Products

E.5.C ICH Q5C:
Quality of Biotechnological Products: Stability Testing of Biotechnological/
Biological Products
E.5.D  ICH Q5D:  
Derivation and Characterisation of Cell Substrates used for Production of Biotechnological/Biological Products

E.5.E  ICH Q5E:  
Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process

E.6.A  ICH Q6A:  
Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances

E.6.B  ICH Q6B:  
Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products

E.7  ICH Q7:  
Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients

E.7.1  “How to do” Document – Interpretation of the ICH Q7a Guide

E.8  ICH Q8 (R2):  
Pharmaceutical Development

E.9  ICH Q9:  
Quality Risk Management

E.10  ICH Q10:  
Pharmaceutical Quality System

E.10.1 Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers

F  PIC/S Guidelines

F.1  PIC/S PI 006-3:  
Recommendations on Validation Master Plan  
Installation and Operational Qualification  
Non-Sterile Process Validation  
Cleaning Validation

F.2  PIC/S PI 007-5:  
Recommendation on the Validation of Aseptic Processes

F.3  PIC/S PI 011-3:  
Good Practices for Computerised Systems in Regulated “GXP” Environments
F.4  PIC/S PI 023-2:  
Aide-mémoire  
Inspection of Pharmaceutical Quality Control Laboratories

F.5  PIC/S PE 008-4:  
Explanatory notes  
for pharmaceutical manufacturers on the preparation of a Site Master File

F.6  PIC/S PI 009-3:  
Aide-mémoire  
Inspection of Utilities

F.7  PIC/S PI 028-1:  
Aide-mémoire  
GMP Inspection Related to Packaging

F.8  PIC/S PI 032-2:  
Recommendation  
GMP Annex 1 Revision 2008,  
Interpretation of Most Important Changes for the Manufacture of Sterile Medicinal Products

G  GMP of other Regions  
This chapter is supplied on CD-ROM and online (www.gmp-manual.com) only.

G.1  WHO Guidelines

G.1.1  Quality assurance of pharmaceuticals

G.1.1.1  1. WHO good manufacturing practices: main principles for pharmaceutical products

G.1.1.2  2. WHO good manufacturing practices: starting materials

G.1.1.3  3. WHO good manufacturing practices: specific pharmaceutical products

G.1.1.4  4. Inspection

G.1.1.5  5. Hazard and risk analysis in pharmaceutical products

G.1.1.6  6. Sampling operations

G.1.2  Guide to good storage practices for pharmaceuticals

G.1.3  Annex 5  
WHO good distribution practices for pharmaceutical products

G.2  Canada  
G.2.1 Annex 1
to the Current Edition of the Good Manufacturing Practices Guidelines – 
Selected Category IV Monograph Drugs 
(GUI-0066)

G.2.2 Annex 2
 to the Current Edition of the Good Manufacturing Practices Guidelines –  
Schedule D Drugs, Biological Drugs Including Fractionated Blood Products  
(GUI-0027)

G.2.3 Annex 3
 to the Current Edition of the Good Manufacturing Practices Guidelines –  
Schedule C Drugs  
(GUI-0026)

G.2.4 Annex 4
 to the Current Edition of the Good Manufacturing Practices Guidelines –  
Veterinary Drugs  
(GUI-0012)

G.2.5 Annex 5
 to the Current Edition of the Good Manufacturing Practices Guidelines –  
Positron Emitting Radiopharmaceuticals (PER’s)  
(GUI-0071)

G.2.6 Annex 13
 to the Current Edition of the Good Manufacturing Practices Guidelines –  
Drugs Used in Clinical Trials  
(GUI-0036)

G.2.7 Annex 14
 to the Current Edition of the Good Manufacturing Practices Guidelines –  
Schedule D Drugs, Human Blood and Blood Components  
(GUI-0032)